Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
28 January 2021 - 12:00AM
Business Wire
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical
company focused on the treatment of serious diseases in which
protein growth factors play a fundamental role, today announced a
presentation at the 2021 TGFβ for Immuno-Oncology Drug Development
Summit.
“Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary
Resistance to Checkpoint Inhibition Therapy” will be presented on
January 28th, 2021 at 12:30 PM EST. The presentation will provide
an overview of the preclinical data demonstrating selective
inhibition of TGFβ1 activation with SRK-181-mIgG1 (murine version
of SRK-181) induces combination treatment effects with anti-PD-1 on
tumor growth in checkpoint inhibition therapy-resistant tumors as
well as an improved preclinical toxicity profile compared to less
selective TGFβ inhibition.
Scholar Rock will also be participating in a panel discussion
titled “Debating the Best Approach to Target TGF-β” on January
27th, 2021 at 10:45 am EST.
About SRK-181
SRK-181 is a potent and highly selective inhibitor of TGFβ1
activation and is an investigational product candidate being
developed to overcome primary resistance to checkpoint inhibitor
therapy, such as anti-PD-(L)1 antibodies. TGFβ1 is the predominant
TGFβ isoform expressed in many human tumors, particularly for those
tumors where checkpoint therapies are currently approved. Based on
analyses of human tumors that are resistant to anti-PD-(L)1
therapy, data suggests TGFβ1 is a key contributor to excluding
immune cell entry into the tumor microenvironment, thereby
preventing normal immune function. Scholar Rock believes SRK-181
has the potential to overcome this immune cell exclusion and induce
tumor regression when administered in combination with anti-PD-(L)1
therapy. By specifically targeting the latent TGFβ1 isoform,
Scholar Rock hypothesizes that SRK-181 can increase the therapeutic
window by potentially avoiding toxicities associated with
non-selective TGFβ inhibition. A Phase 1 proof-of-concept clinical
trial in patients with locally advanced or metastatic solid tumors
is ongoing. The effectiveness and safety of SRK-181 have not been
established and SRK-181 has not been approved for any use by the
FDA or any other regulatory agency.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative medicines
for the treatment of serious diseases in which signaling by protein
growth factors plays a fundamental role. Scholar Rock is creating a
pipeline of novel product candidates with the potential to
transform the lives of patients suffering from a wide range of
serious diseases, including neuromuscular disorders, cancer,
fibrosis and anemia. Scholar Rock’s approach to targeting the
molecular mechanisms of growth factor activation enabled it to
develop a proprietary platform for the discovery and development of
monoclonal antibodies that locally and selectively target these
signaling proteins at the cellular level. By developing product
candidates that act in the disease microenvironment, the Company
intends to avoid the historical challenges associated with
inhibiting growth factors for therapeutic effect. Scholar Rock
believes its focus on biologically validated growth factors may
facilitate a more efficient development path. For more information,
please visit www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
potential of SRK-181 to address certain patient unmet needs and the
ability of any product candidate to perform in humans in a manner
consistent with earlier nonclinical, preclinical or clinical trial
data. The use of words such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,”
“intend,” “future,” “potential,” or “continue,” and other similar
expressions are intended to identify such forward-looking
statements. All such forward-looking statements are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include Scholar Rock’s ability to provide the
financial support, resources and expertise necessary to identify
and develop product candidates on the expected timeline, the data
generated from Scholar Rock’s nonclinical and preclinical studies
and clinical trials as well as those risks more fully discussed in
the section entitled "Risk Factors" in Scholar Rock’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2020, as
well as discussions of potential risks, uncertainties, and other
important factors in Scholar Rock’s subsequent filings with the
Securities and Exchange Commission. Any forward-looking statements
represent Scholar Rock’s views only as of today and should not be
relied upon as representing its views as of any subsequent date.
All information in this press release is as of the date of the
release, and Scholar Rock undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210127005110/en/
Scholar Rock Contact: Investors/Media Catherine Hu
chu@scholarrock.com
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024